Soleno Therapeutics’ (SLNO) Neutral Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald restated their neutral rating on shares of Soleno Therapeutics (NASDAQ:SLNO) in a research note published on Monday morning,Benzinga reports. They currently have a $53.00 price target on the stock, down from their previous price target of $123.00.

Other equities analysts have also issued research reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Soleno Therapeutics in a research note on Thursday, January 22nd. Robert W. Baird set a $107.00 price target on Soleno Therapeutics in a research note on Tuesday, January 13th. Zacks Research lowered Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 3rd. Oppenheimer cut their price target on Soleno Therapeutics from $110.00 to $80.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 18th. Finally, TD Cowen cut their price target on Soleno Therapeutics from $120.00 to $85.00 and set a “buy” rating on the stock in a research note on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $97.10.

Soleno Therapeutics Price Performance

Soleno Therapeutics stock opened at $52.25 on Monday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 5.55 and a current ratio of 5.80. The firm has a market cap of $2.70 billion, a P/E ratio of 227.18 and a beta of -2.81. The business’s fifty day moving average is $37.99 and its two-hundred day moving average is $47.81. Soleno Therapeutics has a 52 week low of $29.43 and a 52 week high of $90.32.

Soleno Therapeutics (NASDAQ:SLNO) last posted its quarterly earnings data on Wednesday, February 25th. The company reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.16. The business had revenue of $91.73 million during the quarter, compared to analyst estimates of $88.55 million. Equities research analysts forecast that Soleno Therapeutics will post -3.72 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Soleno Therapeutics

Large investors have recently made changes to their positions in the company. Avoro Capital Advisors LLC increased its holdings in Soleno Therapeutics by 12.5% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,900,000 shares of the company’s stock valued at $134,270,000 after purchasing an additional 322,223 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Soleno Therapeutics in the fourth quarter valued at about $38,000. Seven Fleet Capital Management LP bought a new stake in Soleno Therapeutics in the fourth quarter valued at about $6,023,000. Virtu Financial LLC bought a new stake in Soleno Therapeutics in the fourth quarter valued at about $1,059,000. Finally, Empowered Funds LLC bought a new stake in Soleno Therapeutics in the fourth quarter valued at about $69,000. Institutional investors and hedge funds own 97.42% of the company’s stock.

Soleno Therapeutics News Summary

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Neurocrine agreed to acquire Soleno for $53.00 per share in cash, valuing the company at about $2.9 billion; the deal brings Soleno’s VYKAT XR into Neurocrine’s rare‑disease/endocrinology franchise and is the main catalyst for the stock’s upward move. PR Newswire deal release
• Positive Sentiment: Market coverage and headlines framed the transaction as a strategic fit and a significant cash premium, spurring buying interest and momentum into today’s session. Fool coverage
• Neutral Sentiment: Cantor Fitzgerald reaffirmed a neutral rating and set a $53 price target (down from $123), which essentially prices the stock at the deal level and leaves little reported analyst upside beyond the offer. Benzinga note
• Neutral Sentiment: Trading was briefly halted early this morning for “news pending” ahead of the announcement, consistent with a planned deal release and conference call. (Company / market process item.)
• Negative Sentiment: Multiple securities‑litigation notices and class action filings allege that Soleno made material misstatements or omissions relating to its Phase 3 program and the commercial launch of DCCR (VYKAT XR); several law firms (Rosen, Hagens Berman, Bronstein, Faruqi, Schall, others) are soliciting plaintiffs and investigating fiduciary fairness of the transaction — creating potential legal exposure and distracting management. Rosen Law Firm notice Hagens Berman filing
• Negative Sentiment: Several shareholder‑protection firms are investigating whether the $53/ share deal is fair to public shareholders and whether the board fulfilled fiduciary duties; potential lawsuits could complicate or delay closing and may result in additional costs or deal renegotiation. Ademi Firm alert

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.